Close Menu

NEW YORK (GenomeWeb) – Dutch molecular diagnostics firm SkylineDx today announced it has received CE-IVD certification for its MMprofiler.

The test determines prognosis risk for multiple myeloma patients based on the SKY92 gene signature and is used to stratify patients into standard and high-risk groups. The firm said in a statement that the gene signature outperforms current standard risk indicators for myeloma, such as serum albumen levels and fluorescent in situ hybridization.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.